Transgene Announces the Nomination of Two New Board Members

Regulatory News:

Transgene SA (Paris:TNG), a biopharmaceutical company that develops immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, today announced that two new members of the board were elected at the Annual General Meeting held on June 19, Prof. Laurence Zitvogel and Mr Jean-Luc Bélingard, in replacement respectively of Prof. Christian Bréchot (MD) and Mr Georges Hibon who did not stand for reelection.

Ms Laurence Zitvogel (MD) is a professor of immunology and biology at Paris University (Université de Paris Sud). An oncologist and researcher at Institut Gustave Roussy since 1995, she is internationally renowned for her work in anti-tumor immunology; she has led Phase 1 and Phase 2 clinical studies in cancer immunotherapy and deciphered the mechanisms of immunogenic tumor death triggered by cytotoxic agents used in oncology. Laurence Zitvogel is also Research Director at INSERM (Institut National de la Santé et de la Recherche Médicale) and Co-Director of the Center of Clinical Investigations of Biotherapies, a common venture between Institut Gustave Roussy, Institut Curie and INSERM. She holds numerous prizes and awards (amongst them the INSERM Research Prize) and is Chevalier de la Légion d’Honneur and a member of the Académie de Médecine.

Mr Jean-Luc Bélingard has been Chairman and Chief Executive Officer of bioMérieux S.A since January 2011. A graduate of the Ecole des Hautes Etudes Commerciales (HEC) of Paris (1971) he holds a Master of Business Administration (MBA) from Cornell University, U.S.A. (1974). Since then, he has held management positions at Merck, Sharp and Dohme (1974-1983), Roche France ("Président du Directoire”, 1983-1990), F. Hoffman-La Roche Ltd. (Member of the Executive Committee, 1990-1998), Roche Diagnostics, Basel (Chief Executive Officer, 1990-1998), bioMérieux-Pierre Fabre (Chief Executive Officer, 1999-2001), Ipsen Group (Chairman and Chief Executive Officer, 2002-2010).

"We are delighted and honored to have Laurence Zitvogel and Jean-Luc Bélingard join our Board of Directors. Their respective expertise will unquestionably be important in helping us achieve our next development steps and in determining our corporate, medical and scientific strategy” stated Philippe Archinard, Chairman and CEO of Transgene. He added: "We are extremely grateful and would like to thank Christian Bréchot and Georges Hibon for their very valuable contribution to the company during the time they have been members of our Board of Directors.”

About Transgene:
Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a biopharmaceutical company. We create, develop and manufacture targeted immunotherapeutics for the treatment of cancers and infectious diseases. Our products are major technological breakthroughs that use well tolerated viruses to indirectly or directly kill infected or cancerous cells. Our four most advanced products have generated proof of concept data in randomized clinical studies: in lung cancer (TG4010), liver cancer (Pexa-Vec), hepatitis C (TG4040) and HPV-related cervical lesions (TG4001). We have concluded strategic agreements for the development of three of these products: an option agreement with Novartis for the development of TG4010, an in-licensing agreement with US-based Jennerex, Inc. to develop and market Pexa-Vec and a strategic collaboration with EORTC to develop TG4001 in cancer of the oropharynx. We also have a non-exclusive agreement with Sanofi/Genzyme for the future commercial production of our products. Most of our 280 employees are based in Strasbourg, France, and we have operations in Lyon, China and the USA. Additional information about Transgene is available at www.transgene.fr.

Société anonyme au capital de 72.886.317 € – R.C. Strasbourg B 317 540 581
400 boulevard Gonthier d’Andernach – Parc d’Innovation - CS80166 – 67405 ILLKIRCH GRAFFENSTADEN CEDEX (France)
Tél : + 33 (0)3 88 27 91 00